Nkarta, Inc. (NKTX) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $1.70 - $3.72

6.2 Year NKTX Performance Metrics:

Total Return (with DRIP): -94.5% (-37.42% CAGR)

Total Return (no DRIP): -94.5% (-37.42% CAGR)

Share Price: -94.5% (-37.42% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $547

Total Return $ (with DRIP): -$9,453

NKTX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

NKTX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for NKTX

Based on past 6.2-year performance, here are NKTX growth metrics:

Share price CAGR of -37.42%
Dividend CAGR of +0%

Using NKTX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	NKTX (DRIP)	NKTX - No DRIP
Current Price	$2.62	$2.62
Start Shares	3,816.79	3,816.79
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	3,816.79	3,816.79
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.02	$2.62
Total Dividends	$0	$0
Final Value	$92	$10,000

Estimated Future Value + Dividends - NKTX

NOTE: Above numbers are our estimate based on NKTX's Dividend and Price CAGR over past 6.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Nkarta, Inc. (NKTX) had its IPO on , and is traded on NASDAQ stock exchange.

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company’s work centers on engineered cell therapies designed to target autoimmune diseases and, in some programs, hematologic cancers. Nkarta’s pipeline includes product candidates built to improve NK-cell recognition, persistence, and activity through proprietary cell engineering and expansion technologies. Its lead programs are being developed for autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and ANCA-associated vasculitis, reflecting a broader effort to address diseases driven by abnormal immune activity. Based in South San Francisco, California, Nkarta operates as a biotechnology company within the healthcare sector and is dedicated to advancing scalable, ready-to-use cell therapy platforms for clinical use.

NKTX website: https://www.nkartatx.com